EUVIMEDEUVIMED entdecken
Crossref

Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy

Qi Zhang, Juan Zhao, Tingwei Xu iD

Fundamental & Clinical Pharmacology · 2023

DOI: 10.1111/fcp.12877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2023. Verfasst von Qi Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Glioblastoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Xiangyang Central Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma is characterized by extensive vascularization and is highly resistant to current therapy. Identification of drugs that target tumor directly and angiogenesis processes present an effective therapeutic strategy for glioblastoma. Mnk kinase is required for the activation of eukaryotic initiation factor 4E (eIF4E), which mediates translation of oncogenic proteins. We investigated the effects of tomivosertib, a novel MAPK‐interacting kinase (MNK) inhibitor, on glioblastoma angiogenesis, growth, and survival. We found that tomivosertib inhibited growth and induced caspase‐dependent apoptosis in various glioblastoma cell lines. Tomivosertib disrupted glioblastoma endothelial cell capillary network formation, growth, and survival. Mechanistically, tomivosertib acted on glioblastoma via suppressing MNK‐dependent eIF4E phosphorylation and activation in tumor and endothelial cells. We further found that temozolomide activated eIF4E and this was reversed by tomivosertib. Using glioblastoma xenograft mouse model, we demonstrated that temozolomide and tomivosertib combination had higher efficacy than tomivosertib alone. Of note, tomivosertib inhibited glioblastoma angiogenesis and decreased p‐eIF4E level in mice. We finally showed that p‐eIF4E activation was a common molecular feature in glioblastoma patients. Our pre‐clinical findings suggest that tomivosertib is a useful addition to the treatment armamentarium for glioblastoma and that targeting MNK‐eIF4E pathway represents a therapeutic strategy to overcome glioblastoma chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesGlioblastomaHumansAnimalsMiceEukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsTemozolomideEndothelial CellsCell Line, TumorPhosphorylationPyridinesPyrimidines

Stichwörter der Autor:innen

MNKangiogenesiseIF4Eglioblastomatomivosertib

Substanzen

Protein Serine-Threonine KinasesEukaryotic Initiation Factor-4EIntracellular Signaling Peptides and ProteinsTemozolomidetomivosertibPyridinesPyrimidines

Autor:innen und Institutionen

  • Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China.
  • Department of Neurosurgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, 14 Dong Street, Xiangcheng District, Xiangyang, 441021, Hubei Province, China.

ORCID-Profile: Tingwei Xu

Förderung

  • Xiangyang Central Hospital

Zitieren

APA

Zhang, Q., Zhao, J., & Xu, T. (2023). Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12877

Vancouver

Zhang Q, Zhao J, Xu T. Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy. Fundamental & Clinical Pharmacology. 2023. doi:10.1111/fcp.12877

BibTeX
@article{Zhang2023,
  author = {Zhang, Qi and Zhao, Juan and Xu, Tingwei},
  title = {Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/fcp.12877}
}
Kostenlos starten →